Gilead Advancing Access®: What to Know | Prism Health North Texas
Gilead loses monopoly control of its blockbuster hepatitis C medicine in China | Médecins Sans Frontières Access Campaign
Huffington Post Op-ed: Gilead Sciences: Price Gouger, Tax Dodger - Americans For Tax Fairness
Gilead to Slice List Prices of Liver Drugs - WSJ
Gilead reports 3% revenue growth in Q1 2022
Patients sue Gilead, saying drug company intentionally delayed safer HIV medicine - Los Angeles Times
United States v. Gilead: The Fight for PrEP | Bill of Health
Gilead says generic Truvada will be available in 2020
Pharma giant Gilead sued for 'withholding' safer HIV drug | PinkNews
A Drug is 90 Percent Effective at Preventing HIV.… | Arnold Ventures
PrEP's Still Too Costly For Many People At Risk For HIV : Shots - Health News : NPR
More evidence remdesivir helps some coronavirus patients | CNN
COVID-19 Drug Remdesivir Priced At More Than $3,100 Per Patient : Shots - Health News : NPR
Gilead Will Begin Marketing Lower Cost Hepatitis C Drugs in January – RWC-340B
Gilead Sciences, Inc.
Gilead prices remdesivir at $2,340 per patient for developed countries
Federal government sues Gilead Sciences, alleging patent infringement on HIV drugs
Gilead bags EU approval for next-generation HIV drug - PMLiVE
Gilead Will Donate Truvada to U.S. for H.I.V. Prevention - The New York Times
Gilead Revenue Soars on Hepatitis C Drug - The New York Times
New Data On Gilead's Covid-19 Drug Is Positive, but Inconclusive | Barron's
